Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...